This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Looking into Sagimet's potential drug candidate denifanstat for the treatment of Nonalcoholic steatohepatitis (NASH)

Ticker(s): SGMT, NVO

Who's the expert?

Institution: The lowa Clinic

  • General gastroenterologist working in the Midwest at a large multi clinic practice that is independently owned. 
  • Sees a variety of Gl conditions including significant inflammatory bowel disease, significant liver disease, IBS, and others.
  •  Participated in market research surveys and interviews for many years

Interview Goal
to discuss the standard of care and the potential of Denifanstat, an investigational fatty acid synthase (FASN) inhibitor being developed by Sagimet Biosciences for the treatment of NASH.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.